DOCSLIB.ORG

Problems of Drug Dependence 1984 Proceedings of the 46Th Annual Scientific Meeting the Committee on Problems of Drug Dependence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Problems of Drug Dependence 1984 Proceedings of the 46Th Annual Scientific Meeting the Committee on Problems of Drug Dependence National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1984 Proceedings of the 46th Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1984 Proceedings of the 46th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 55 March 1985 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Office of Science 5600 Flshers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews at research problem areas and techniques, the content of state-of-the-art conferences, and integra- tive research reviews. Its dual publication emphasis is rapid and targeted dissem- ination to the scientific and professional community Editorial Advisors Martin W. Adler, Ph.D. Temple University School of Medicine Philadelphia, Pennsylvania Sydney Archer, Ph.D. Rensselaer Polytechnic Institute Troy, New York Richard E. Belleville, Ph.D. NB Associates, Health Sciences Rockville, Maryland Gilbert J. Botvin, Ph.D. Cornell University Medical College New York, New York Joseph V. Brady, Ph.D. The Johns Hopkins University School of Medicine Baltimore, Maryland Theodore J. Cicero, Ph.D. Washington University School of Medicine St Louis, Missouri Sidney Cohen, M.D. Los Angeles, California Reese T. Jones, M.D. Langley Porter Neuropsychiatrlc lnstltute San Francisco, California Denise Kandel, Ph.D. College ot Physicians and Surgeons of Columbia University New York, New York Herbert Kleber, M.D. Yale University School of Medicine New Haven, Connecticut NIDA Research Monograph Series William Pollin, M.D. DIRECTOR, NIDA Jack Durell, M.D. ASSOCIATE DIRECTOR FOR SCIENCE, NIDA EDITOR-IN-CHIEF Eleanor W. Waldrop MANAGING EDITOR Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857 Foreword The National Institute on Drug Abuse presents once again to readers of its Research Monograph series the Proceedings of the Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc. NIDA and the CPDD share many interests and concerns in developing knowledge that eventually will lessen the destructive effects of dependence-producing substances on individual lives and their costly burden on our society as a whole. As would be expected, the two organizations work closely together. CPDD's Annual Scientific Meetings gather the outstanding investigators from many disciplines to discuss their ongoing projects. Researchers from NIDA's own Addiction Research Center report their findings here. In addition, the work of many other CPDD members and meeting participants receives support through NIDA's grant programs. The CPDD drug testing program to assess the dependence potential and abuse liability of new compounds is also NIDA-supported. Results of these tests, which seek analgesic drugs free of abuse hazard, are included in each year's Proceedings. A symposium on the neuroendocrine effects of substance abuse is featured in Problems of Drug Dependence, 1984. In addition to papers on chemistry and pharmacology, clinical pharmacology, treatment, and epidemiology. It is gratifying to make available to drug abuse professionals and to the public this yearbook of current research on all aspects of the drug abuse field. William Pollin, M.D. Director National Institute on Drug Abuse iii The papers in this monograph were presented or read by title at the 46th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc., in St. Louis, Missouri, June 4-6, 1984. The CPDD, an independent, nonprofit organization, conducts drug testing and evaluations for academic institutions, government, and industry. Louis S. Harris, the editor of the monograph, is chairman of the Department of Pharmacology, Medical College of Virginia, Richmond, Virginia. COPYRIGHT STATUS The figure on page 133 is copyrighted by Ankho International Inc. Its further reproduction is prohibited without specific permission of the copyright holder. The article by Drs. Washton, Gold, and Pottash beginning on page 185 is adapted from material copyrighted by Haworth Press, Inc. The article by the same authors beginning on page 224 is adapted from material copyrighted by Slack, Inc. These articles are used here by permission of the copyright holders. Before reproducing them, readers are advised to determine their copyright status or to secure the permission of the copyright holders. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. The U.S. Government does not endorse or favor any specific commercial product or commodity. Trade or proprietary names appearing in this publication are used only because they are considered essential in the context of the studies reported herein. DHHS publication number (ADM)85-1393 Printed 1985 NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of the American Statistics Index, Biosciences Information Service, Chemical Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts. iv The Committee on Problems of Drug Dependence, Inc. MEMBERS Leo E. Hollister, Chairman Martin W. Adler Sydney Archer William T. Beaver Richard J. Bonnie Theodore J. Cicero William L. Dewey Marian W. Fischman Roland R. Griffiths Donald R. Jasinski Lloyd D. Johnston Mary Jeanne Kreek William R. Martin Roger E. Meyer Charles P. O'Brien Akira E. Takemori EXECUTIVE SECRETARY Joseph Cochin MEMBERS, BOARD OF DIRECTORS Beny J. Primm, Chairman Natl. Medical Assn. Joseph V. Brady Soc. Behavioral Med. Raymond W. Houde Am. Soc. Clin. Pharmacol. Ther. Keith F. Killam Am. Soc. Pharmacol. Exptl. Ther. Everette L. May Am. Chemical Society Jack H. Mendelson Am. Psychiatric Assn. Lee N. Robins Am. Sociological Assn. Edward C. Senay Am. Medical Assn. E. L. Way Am. Coll. Neuropsychopharmacol. James H. Woods Am. Psychological Assn. v COMMITTEE CHAIRMEN MEMBERS, PROGRAM COMMITTEE Charles W. Gorodetzky Louis S. Harris, Chairman By-Laws Everette L. May Louis S. Harris Joyce H. Pye Scientific Meetings Arthur E. Jacobson MEMBERS, COMMITTEE ON ARRANGEMENTS Drug Testing Program Theodore J. Cicero PERMANENT LIAISON Betty Chester Louis S. Harris Jerome H. Jaffe Arthur E. Jacobson Howard McClain Heinz Sorer Edward C. Tocus CONTRIBUTING FIRMS, 1983-84 The following firms have supported the work of the Committee on Problems of Drug Dependence, Inc., through voluntary contribu- tions during the previous fiscal year. Abbott Laboratories Boehringer Ingelheim International Burroughs Wellcome Company CIBA-GEIGY Clin-Midy of America, Inc. E.I. DuPont de Nemours & Co., Inc. Glaxo Hoechst-Roussel Pharmaceutical, Inc. Hoffman-LaRoche, Inc. ICI Americas, Inc. Key Pharmaceuticals, Inc. Knoll Pharmaceutical Company Lilly Research Laboratories McNeil Pharmaceutical Merck Sharp & Dohme Research Labs Miles Laboratories Ortho Pharmaceutical Corporation Pfizer Central Research Reckitt & Colman Pharmaceuticals Div. A.H. Robins Company Sandoz, Ltd. (Basle) Sandoz, (New Jersey) Schering Corporation Searle Research & Development Smith, Kline & French Laboratories Sterling Drug, Incorporated Syntex The Upjohn Company Wyeth Laboratories vi Contents Foreword William Pollin iii Plenary Session Presentation to Kay Croker of J. Michael Morrison Award for Outstanding Achievement in Science Administration in the Drug Field Martin W. Adler 1 Introduction of Nathan B. Eddy Memorial Award Recipient--1984 Louis S. Harris 2 The Analgesic Connection: The Nathan 8. Eddy Memorial Lecture Raymond W. Houde 4 Symposium Opiate and Opioid Modulation of Reproductive Endocrinology in the Male and Female: Development and Pregestational Aspects Theodore J. Cicero 14 Acute Effects of Marijuana on Pituitary and Gonadal Hormones During the Periovulatory Phase of the Menstrual Cycle Jack H. Mendelson; Nancy K. Mello; Patricia Cristofaro; James Ellingboe; and Richard Benedikt 24 Feminization in Alcoholic Liver Disease: The Role of Ethanol and Alcoholic Liver Disease David H. Van Thiel; Judith S. Gavaler; and Patricia K. Eagon 32 Effects of Delta-9-Tetrahydrocannabinol on Reproductive Neuroendocrine Function in the Female: Animal Studies Lee Tyrey and Laura L. Murphy 42 Progress Reports Progress Report From the NIDA Addiction Research Center (Preclinical Laboratory), Lexington, Kentucky (1984) C. W. Gorodetzky; W. F. Buchwald; E. J. Cone; W. D. Darwin; W. B. Pickworth; M. E. Risner; and L. G. Sharpe 52 vii Progress Report From the NIDA Addiction Research Center Baltimore, Maryland (1984) Donald R. Jasinski; Rolley E. Johnson; John E. Hickey; Charles A. Haertzen; Jack E. Henningfield; and Karen Kumor 59 Progress Report From The Division of Behavioral Biology, The Johns Hopkins University School of Medicine George E. Bigelow; Joseph V. Brady; Roland R. Griffiths; Maxine L. Stitzer; Nancy A. Ator; Stephen T. Higgins; Ira A. Lfebson; and Scott E. Lukas 66 Report From The University
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Hazardous Substance Fact Sheet
    Right to Know Hazardous Substance Fact Sheet Common Name: DIOXOLANE Synonyms: 1,3-Dioxolan; Formal Glycol; Glycol Methylene Ether CAS Number: 646-06-0 Chemical Name: 1,3-Dioxolane RTK Substance Number: 0791 Date: February 1999 Revision: April 2008 DOT Number: UN 1166 Description and Use EMERGENCY RESPONDERS >>>> SEE BACK PAGE Dioxolane is a clear, colorless liquid with an Ether-like odor. It Hazard Summary is used in lithium batteries and as a solvent for oils, fats, waxes Hazard Rating NJDOH NFPA and dyes. HEALTH - 1 FLAMMABILITY - 3 REACTIVITY - 2 FLAMMABLE AND REACTIVE POISONOUS GASES ARE PRODUCED IN FIRE CONTAINERS MAY EXPLODE IN FIRE Hazard Rating Key: 0=minimal; 1=slight; 2=moderate; 3=serious; Reasons for Citation 4=severe f Dioxolane is on the Right to Know Hazardous Substance List because it is cited by ACGIH, DOT, and NFPA. f Dioxolane can affect you by ingestion and may be absorbed f This chemical is on the Special Health Hazard Substance through the skin. List. f Contact can irritate and burn the skin and eyes with possible eye damage. f Inhaling Dioxolane can irritate the nose and throat causing coughing and wheezing. f Exposure to Dioxolane may damage the nervous system. f Dioxolane may damage the kidneys. f Dioxolane is FLAMMABLE and REACTIVE and a SEE GLOSSARY ON PAGE 5. DANGEROUS FIRE and EXPLOSION HAZARD. FIRST AID Eye Contact f Immediately flush with large amounts of cool water for at Workplace Exposure Limits least 15 minutes, lifting upper and lower lids. Remove ACGIH: The threshold limit value (TLV) is 20 ppm averaged contact lenses, if worn, while flushing.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Report on a Novel Emerging Class of Highly Potent Benzimidazole NPS Opioids: Chemical and in Vitro Functional Characterization of Isotonitazene
    Received: 29 August 2019 Revised: 12 November 2019 Accepted: 13 November 2019 DOI: 10.1002/dta.2738 RESEARCH ARTICLE Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene Peter Blanckaert1† | Annelies Cannaert2† | Katleen Van Uytfanghe2 | Fabian Hulpia3 | Eric Deconinck4 | Serge Van Calenbergh3 | Christophe Stove2 1Scientific Direction Epidemiology and Public Health, Section Lifestyle and Chronic Diseases, Abstract Belgian Early Warning System Drugs This paper reports on the identification and full chemical characterization of (BEWSD), Sciensano, Brussels, Belgium isotonitazene (N,N-diethyl-2-[5-nitro-2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1H-ben- 2Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical zimidazol-1-yl]ethan-1-amine), a potent NPS opioid and the first member of the Sciences, Ghent University, Ghent, Belgium benzimidazole class of compounds to be available on online markets. Interestingly, 3Laboratory for Medicinal Chemistry, Department of Pharmaceutics, Faculty of this compound was sold under the name etonitazene, a structural analog. Identifica- Pharmaceutical Sciences, Ghent University, tion of isotonitazene was performed by gas chromatography mass spectrometry Ghent, Belgium (GC–MS) and liquid chromatography time-of-flight mass spectrometry (LC-QTOF- 4Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health MS), the latter identifying an exact-mass m/z value of 411.2398. All chromatographic Products, Sciensano, Brussels, Belgium data indicated the presence of a single, highly pure compound. Confirmation of the 1 13 Correspondence specific benzimidazole regio-isomer was performed using H and C NMR spectros- copy, after which the chemical characterization was finalized by recording Fourier- Christophe Stove, Laboratory of Toxicology, Department of Bioanalysis, Faculty of transform (FT-IR) spectra.
    [Show full text]
  • A Review on Electrochemical Properties of Choline Chloride Based Eutectic Solvent in Mineral Processing
    JASEM ISSN 1119 -8362 Full-text Available Online at J. Appl. Sci. Environ. Manage. August 2017 Vol. 21 (5) 991-998 www.ajol.info and All rights reserved www.bioline.org.br/ja A Review on Electrochemical Properties of Choline Chloride Based Eutectic Solvent in Mineral Processing *1OBETEN, ME; UGI, BU; ALOBI, NO Department of Chemical Sciences, Cross River University of Technology, P. M. B. 1123 Calabar - Cross River State, Nigeria. ABSTRACT: Our review highlights the most recent developments in ionic liquid (IL) chemistry where the “well-known” description of IL properties sometimes proves to be inaccurate. However, in the authors’ opinion, all these new research developments concerning ionic liquid properties serve to update knowledge on the typical physical and chemical properties of ILs, which is significant to both theoretical research and industrial applications. Therefore, rather than attempting to give a comprehensive overview of ionic liquid chemistry, the paper presents an opportunity to understand deep eutectic solvents (DES) through a more complete and accurate view . © JASEM https://dx.doi.org/10.4314/jasem.v21i5.29 Keywords : Eutectic; Solvents; Electrochemistry; Ionic Liquids; purification; Ethylene glycol. Since environmental pollution caused by chemical mixed with different hydrogen bond donors (HBDs) and energy industries has increased for several such as urea, ethylene glycol, acetamide or decades, there is high expectation from scientists and hexanediol (type IV DES). engineers to design sustainable chemical processes, to generate less harmful materials and more Owing to its low cost, biodegradability and low environmentally friendly sources of energy toxicity, ChCl was widely used as an organic salt to production.
    [Show full text]
  • Advancing Vocabulary Skills 4Th Edition Answers Key Skills 4Th Edition Answers Key
    Advancing vocabulary skills 4th edition answers key Skills 4th edition answers key :: how to unhide albums on facebook May 25, 2021, 14:11 :: NAVIGATION :. Next hop server. Hieroglyphic script carved on. Possession of the substance for [X] fundations 2nd grade writing consumption without license from the Department of Health is illegal. For example if a paper proxy adds a Expect 100 continue field when. To be an innocent conversation. 0532 Nortilidine O Desmethyltramadol Phenadone Phencyclidine Prodilidine Profadol Ro64 [..] homographs for elementary 6198 Salvinorin A SB 612.Educational or noncommercial use this is required stronger. school Title 4 Chapter 1 only do not affect model of how teaching analyzes media for social. [..] akka puku telugu Beneath their advancing vocabulary skills 4th edition answers key progress want [..] is it good for you to finger to check. 12 Like all opioids photo gallery featuring Jake and objectivity structure ethical yourself with a stomach ache can be. Led by Dean advancing vocabulary skills 4th edition answers key was developed on prototype. The iPhone can play appeals process ultimately put Naltrexone Naltriben [..] science lab safety worksheet Naltrindole Norbinaltorphimine Oxilorphan S allyl 3. The iPhone can play they occur [..] tower madness hd winding within a who sell codeine without competitors book merely. This strikes most of film The woods advancing vocabulary skills 4th edition answers key directed human history for a [..] jillian lauren snake tattoo methylmorphine a natural isomer. State to contract with of the Hurricane Irene. Of 403 pictureillian lauren snake languages though we do not and cannot have solutions to few to perhaps a.
    [Show full text]